UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Rhea-AI Summary
UNITY Biotechnology (NASDAQ: UBX) has reported its Q4 and full-year 2024 financial results. The company anticipates receiving 24-week topline data from its Phase 2b ASPIRE study for UBX1325 (foselutoclax) in diabetic macular edema (DME) in Q1 2025, followed by 36-week data in Q2 2025.
Financial highlights include:
- Cash position of $23.2 million as of December 31, 2024 (down from $43.2M in 2023)
- Full-year 2024 net loss of $26.0 million (improved from $39.9M in 2023)
- Q4 2024 net loss of $8.4 million (compared to $4.3M in Q4 2023)
- Research and development expenses decreased to $13.0 million in 2024 (from $20.1M in 2023)
- General and administrative expenses reduced to $15.5 million in 2024 (from $19.0M in 2023)
Positive
- Net loss improved by 34.8% to $26.0M in 2024
- R&D expenses reduced by 35.3% to $13.0M
- G&A expenses decreased by 18.4% to $15.5M
- Cash burn reduced: $20.9M used in 2024 vs $37.1M in 2023
Negative
- Cash position declined 46.3% to $23.2M
- Q4 net loss increased 95.3% to $8.4M
- Significant workforce reduction implemented
- Facility downsizing through sublease of East Grand facility
News Market Reaction 1 Alert
On the day this news was published, UBX declined 4.76%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024.
“We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “DME remains a significant unmet need, and we believe UBX1325 (foselutoclax) has the potential to provide a differentiated treatment option for patients who continue to experience vision loss despite current standard-of-care therapies. With its novel mechanism of action and durable therapeutic profile, UBX1325 could offer meaningful advantages over existing anti-VEGF treatments. The 24-week data as well as the 36-week data will be instrumental in shaping our plans for a potential pivotal trial and advancing our program.”
UBX1325 (foselutoclax) is designed as a novel and durable therapeutic option in DME that acts via a senolytic mechanism of action, with the potential to address shortcomings of the current standard of care, such as high treatment burden and sub-optimal response to treatment.
UNITY anticipates receiving 24-week primary endpoint data in the first quarter of 2025 and 36-week data in the second quarter of 2025. The Phase 2b ASPIRE study in DME is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept. More information about ASPIRE (NCT06011798) can be found here.
Fourth Quarter and Full Year Financial Results
Cash, cash equivalents and marketable securities totaled
Net loss for the twelve months ended December 31, 2024 was
Research and development expenses decreased by
General and administrative expenses decreased by
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 7, 2025, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
| Unity Biotechnology, Inc. | ||||||||||||||||
| Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (Unaudited) | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 3,035 | $ | 3,271 | $ | 13,006 | $ | 20,099 | ||||||||
| General and administrative | 4,251 | 4,406 | 15,460 | 18,966 | ||||||||||||
| Impairment of long-lived assets | 2,705 | — | 2,705 | 5,602 | ||||||||||||
| Total operating expenses | 9,991 | 7,677 | 31,171 | 44,667 | ||||||||||||
| Loss from operations | (9,991 | ) | (7,677 | ) | (31,171 | ) | (44,667 | ) | ||||||||
| Interest income | 309 | 525 | 1,733 | 2,874 | ||||||||||||
| Interest expense | — | — | — | (2,452 | ) | |||||||||||
| Gain on warrant liability | 1,306 | 3,932 | 3,713 | 6,215 | ||||||||||||
| Other expense, net | (64 | ) | (1,119 | ) | (265 | ) | (1,830 | ) | ||||||||
| Net loss | (8,440 | ) | (4,339 | ) | (25,990 | ) | (39,860 | ) | ||||||||
| Other comprehensive gain (loss) | ||||||||||||||||
| Unrealized gain (loss) on marketable debt securities | (24 | ) | 31 | 39 | 227 | |||||||||||
| Comprehensive loss | $ | (8,464 | ) | $ | (4,308 | ) | $ | (25,951 | ) | $ | (39,633 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.50 | ) | $ | (0.28 | ) | $ | (1.54 | ) | $ | (2.70 | ) | ||||
| Weighted-average number of shares used in computing net loss per share, basic and diluted | 16,857,810 | 15,743,772 | 16,827,038 | 14,773,612 | ||||||||||||
| Unity Biotechnology, Inc. | ||||||||
| Condensed Balance Sheets | ||||||||
| (In thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 7,580 | $ | 19,803 | ||||
| Short-term marketable securities | 15,650 | 23,398 | ||||||
| Prepaid expenses and other current assets | 1,037 | 3,404 | ||||||
| Total current assets | 24,267 | 46,605 | ||||||
| Property and equipment, net | 3,456 | 5,082 | ||||||
| Operating lease right-of-use assets | 8,900 | 12,981 | ||||||
| Long-term restricted cash | 896 | 896 | ||||||
| Other long-term assets | 143 | 126 | ||||||
| Total assets | $ | 37,662 | $ | 65,690 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 997 | $ | 1,380 | ||||
| Accrued compensation | 2,096 | 1,841 | ||||||
| Accrued and other current liabilities | 6,167 | 4,619 | ||||||
| Total current liabilities | 9,260 | 7,840 | ||||||
| Operating lease liability, net of current portion | 19,709 | 23,539 | ||||||
| Warrant liability | 2,199 | 5,913 | ||||||
| Total liabilities | 31,168 | 37,292 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 516,820 | 512,773 | ||||||
| Accumulated other comprehensive gain | 15 | (24 | ) | |||||
| Accumulated deficit | (510,343 | ) | (484,353 | ) | ||||
| Total stockholders’ equity | 6,494 | 28,398 | ||||||
| Total liabilities and stockholders’ equity | $ | 37,662 | $ | 65,690 | ||||
Media
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
When will UNITY Biotechnology (UBX) release the ASPIRE study results for UBX1325?
How much cash does UBX have and how long will it last?
What was UBX's net loss for full-year 2024?
How much did UBX reduce its R&D expenses in 2024?
What is the potential advantage of UBX1325 over existing DME treatments?
